GSA Capital Partners LLP Buys Shares of 307,941 CureVac N.V. (NASDAQ:CVAC)

Key Points

• GSA Capital Partners LLP has invested approximately $853,000 in CureVac N.V., acquiring 307,941 shares of the company during the first quarter of the year.
• Shares of CureVac are currently priced at $5.41 with a market capitalization of $1.21 billion, and the company reported a revenue of $0.94 million for the last quarter, falling short of estimates.
• Recent analyst ratings for CureVac have been mixed, with UBS Group downgrading the stock from "strong-buy" to "neutral" and adjusting the price target down to $5.50.

GSA Capital Partners LLP acquired a new stake in CureVac N.V. (NASDAQ:CVAC - Free Report) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 307,941 shares of the company's stock, valued at approximately $853,000. GSA Capital Partners LLP owned about 0.14% of CureVac as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Geode Capital Management LLC boosted its holdings in CureVac by 10.3% in the 4th quarter. Geode Capital Management LLC now owns 241,750 shares of the company's stock valued at $824,000 after purchasing an additional 22,491 shares during the period. Quadrant Capital Group LLC increased its position in shares of CureVac by 61.8% during the fourth quarter. Quadrant Capital Group LLC now owns 50,016 shares of the company's stock worth $171,000 after buying an additional 19,098 shares during the period. Barclays PLC increased its holdings in CureVac by 51.8% during the fourth quarter. Barclays PLC now owns 34,836 shares of the company's stock worth $118,000 after buying an additional 11,890 shares during the last quarter. XTX Topco Ltd grew its stake in CureVac by 90.2% during the fourth quarter. XTX Topco Ltd now owns 24,365 shares of the company's stock valued at $83,000 after acquiring an additional 11,553 shares in the last quarter. Finally, Jump Financial LLC purchased a new position in CureVac during the fourth quarter valued at approximately $55,000. 17.26% of the stock is owned by institutional investors.

CureVac Stock Performance

NASDAQ:CVAC traded down $0.02 during trading hours on Wednesday, reaching $5.46. The company had a trading volume of 209,730 shares, compared to its average volume of 965,207. The company has a debt-to-equity ratio of 0.05, a current ratio of 7.65 and a quick ratio of 7.64. The firm has a market cap of $1.22 billion, a PE ratio of 5.93 and a beta of 2.53. The business's 50 day moving average price is $5.22 and its 200-day moving average price is $4.01. CureVac N.V. has a 1-year low of $2.37 and a 1-year high of $5.72.

CureVac (NASDAQ:CVAC - Get Free Report) last issued its quarterly earnings results on Thursday, May 22nd. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.08). CureVac had a return on equity of 30.89% and a net margin of 35.44%. The firm had revenue of $0.94 million for the quarter, compared to analysts' expectations of $4.27 million. Research analysts forecast that CureVac N.V. will post 0.72 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on CVAC shares. Jefferies Financial Group reaffirmed a "hold" rating and issued a $5.00 target price (down from $7.00) on shares of CureVac in a research report on Friday, June 13th. Citigroup cut shares of CureVac to a "market perform" rating in a research note on Thursday, June 12th. JMP Securities reaffirmed a "market outperform" rating and set a $10.00 price objective on shares of CureVac in a report on Wednesday, May 28th. Citizens Jmp lowered shares of CureVac from a "strong-buy" rating to a "hold" rating in a report on Thursday, June 12th. Finally, UBS Group lowered shares of CureVac from a "strong-buy" rating to a "neutral" rating and cut their target price for the company from $12.00 to $5.50 in a report on Thursday, June 26th. Four research analysts have rated the stock with a hold rating and one has issued a buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $6.83.

About CureVac

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.